Compare PRTH & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTH | BIOA |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 545.8M | 443.9M |
| IPO Year | N/A | 2024 |
| Metric | PRTH | BIOA |
|---|---|---|
| Price | $5.86 | $19.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.00 | ★ $33.33 |
| AVG Volume (30 Days) | 352.7K | ★ 1.0M |
| Earning Date | 03-05-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $932,948,000.00 | $5,917,000.00 |
| Revenue This Year | $10.60 | N/A |
| Revenue Next Year | $7.92 | N/A |
| P/E Ratio | $11.10 | ★ N/A |
| Revenue Growth | ★ 9.51 | N/A |
| 52 Week Low | $4.44 | $2.88 |
| 52 Week High | $12.47 | $24.00 |
| Indicator | PRTH | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 61.35 |
| Support Level | $5.87 | $18.20 |
| Resistance Level | $6.09 | $21.53 |
| Average True Range (ATR) | 0.19 | 1.90 |
| MACD | 0.02 | -0.17 |
| Stochastic Oscillator | 56.64 | 57.54 |
Priority Technology Holdings Inc is a provider of merchant acquiring and commercial payment solutions to small and medium business enterprises in the United States. The company has three reportable segments which are SMB Payments, B2B Payments, and Enterprise Payments. SMB Payments segment which generates the majority of revenue provides full-service acquiring and payment-enabled solutions for B2C transactions, leveraging Priority's proprietary software platform, distributed through ISO; the B2B Payments segment provides AP automation solutions to corporations, software partners, & industry FIs: and Enterprise Payments segment provides embedded payment & treasury solutions to enterprise customers to modernize legacy platforms & accelerate software partners' strategies to monetize payments.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.